Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in pediatric and adult participants who ...
MPR

Valbenazine Fails to Improve Chorea In Dyskinetic Cerebral Palsy Trial

The KINECT-DCP trial evaluated the efficacy and safety of valbenazine in patients with dyskinesia due to cerebral palsy who experience choreiform movements.
Healio

VIDEO: What clinicians should know about causes, symptoms of tardive dyskinesia

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription ...

Neurocrine Biosciences, Inc.: Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety ...